乙型肝炎的个性化治疗。
Personalized treatment of hepatitis B.
作者信息
Lok Anna S
机构信息
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
出版信息
Clin Mol Hepatol. 2015 Mar;21(1):1-6. doi: 10.3350/cmh.2015.21.1.1. Epub 2015 Mar 25.
Abstract
There are seven approved drugs for treatment of hepatitis B. Professional guidelines provide a framework for managing patients but these guidelines should be interpreted in the context of the individual patient's clinical and social circumstances. Personalized management of hepatitis B can be applied based on prediction of the individual patient's risk of cirrhosis and hepatocellular carcinoma to guide the frequency and intensity of monitoring and urgency of treatment. It can also be applied to decisions regarding when to start treatment, which drug to use, and when to stop based on the individual patient's disease characteristics, preference, comorbidities and other mitigating circumstances.
摘要
有七种已获批用于治疗乙型肝炎的药物。专业指南为管理患者提供了一个框架，但这些指南应在个体患者的临床和社会背景下进行解读。基于对个体患者肝硬化和肝细胞癌风险的预测，可以实施乙型肝炎的个性化管理，以指导监测的频率和强度以及治疗的紧迫性。它还可应用于关于何时开始治疗、使用何种药物以及基于个体患者的疾病特征、偏好、合并症和其他缓解情况何时停药的决策。
相似文献
1
Personalized treatment of hepatitis B.乙型肝炎的个性化治疗。
Clin Mol Hepatol. 2015 Mar;21(1):1-6. doi: 10.3350/cmh.2015.21.1.1. Epub 2015 Mar 25.
2
Preventing infection-associated cancer: from bench to hillside.预防感染相关癌症：从实验室到临床实践
J Natl Cancer Inst. 2005 Feb 16;97(4):245-6. doi: 10.1093/jnci/dji059.
3
Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.乙型肝炎病毒相关性肝移植：适应证减少及趋势变化
World J Gastroenterol. 2015 Jul 14;21(26):8140-7. doi: 10.3748/wjg.v21.i26.8140.
4
Hepatitis B therapies and antiviral resistance detection and management.乙型肝炎治疗和抗病毒耐药检测及管理。
Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):693-9. doi: 10.1586/egh.09.64.
5
Introduction to 'Hepatitis B virus heterogeneity--a means to personalized care'.《乙肝病毒异质性——个性化治疗途径》引言
Antivir Ther. 2010;15 Suppl 3:1-2. doi: 10.3851/IMP1618.
6
Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.乙型肝炎病毒相关肝细胞癌治疗期间的乙型肝炎病毒感染管理
World J Gastroenterol. 2015 Jul 21;21(27):8249-55. doi: 10.3748/wjg.v21.i27.8249.
7
Hepatitis B virus infection: current status.乙型肝炎病毒感染：现状
Am J Med. 2005 Dec;118(12):1413. doi: 10.1016/j.amjmed.2005.06.021.
8
Hepatitis B virus infection.乙型肝炎病毒感染
N Engl J Med. 2008 Oct 2;359(14):1486-500. doi: 10.1056/NEJMra0801644.
9
Advances in the diagnosis and treatment of hepatitis B.乙型肝炎诊断与治疗的进展
Curr Opin Infect Dis. 2008 Oct;21(5):508-15. doi: 10.1097/QCO.0b013e32830fb924.
10
[Genotyping of hepatitis B virus and clinical investigation].[乙型肝炎病毒基因分型及临床研究]
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002 Dec;16(4):367-9.
引用本文的文献
1
Hepatitis B virus genotype distribution and mutation patterns: Insights and clinical implications for hepatitis B virus positive patients.乙型肝炎病毒基因型分布及突变模式：对乙型肝炎病毒阳性患者的见解及临床意义
World J Exp Med. 2025 Jun 20;15(2):102395. doi: 10.5493/wjem.v15.i2.102395.
2
Genetic intersection of human leukocyte antigen-DP/DQ and hepatitis B virus-related liver disease: Insights from a multi-clustering study.人类白细胞抗原-DP/DQ与乙型肝炎病毒相关肝病的遗传交集：一项多聚类研究的见解
World J Gastroenterol. 2025 Apr 28;31(16):102511. doi: 10.3748/wjg.v31.i16.102511.
3
Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms.使用平铺扩增子（HEPTILE）对乙型肝炎病毒进行全基因组测序，并在Illumina和Nanopore平台上基于探针进行富集。
Sci Rep. 2025 Feb 17;15(1):5795. doi: 10.1038/s41598-025-87721-1.
4
Personalized medicine and nutrition in hepatology for preventing chronic liver disease in Mexico.墨西哥肝病学中预防慢性肝病的个性化医疗与营养
Front Nutr. 2024 May 9;11:1379364. doi: 10.3389/fnut.2024.1379364. eCollection 2024.
5
Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases.用于嗜肝性传染病的肝芯片应用进展与挑战
Micromachines (Basel). 2021 Jul 19;12(7):842. doi: 10.3390/mi12070842.
6
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.亚洲地区使用替诺福韦艾拉酚胺治疗慢性乙型肝炎病毒感染的专家综述。
J Gastroenterol. 2020 Sep;55(9):811-823. doi: 10.1007/s00535-020-01698-4. Epub 2020 Jul 14.
7
ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens.ATI-2173，一种新型肝靶向非链终止核苷酸，用于乙型肝炎病毒治疗方案。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00836-20.
8
Determination of liver fibrosis stages in Egyptian chronic hepatitis B patients by a noninvasive tool.利用无创工具确定埃及慢性乙型肝炎患者的肝纤维化分期。
Turk J Med Sci. 2019 Aug 8;49(4):1145-1150. doi: 10.3906/sag-1812-165.
9
[Association of baseline alanine aminotransferase levels with therapeutic effects of entecavir and interferon- in patients with chronic hepatitis B].[慢性乙型肝炎患者基线丙氨酸氨基转移酶水平与恩替卡韦和干扰素治疗效果的关联]
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Feb 28;39(2):150-155. doi: 10.12122/j.issn.1673-4254.2019.09.04.
10
Development and validation of an LC-MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies.建立并验证了一种 LC-MS/MS 方法，用于定量检测大鼠血浆中的 NC-8，并将其应用于药代动力学研究。
J Food Drug Anal. 2018 Jan;26(1):401-408. doi: 10.1016/j.jfda.2017.09.003. Epub 2017 Nov 11.
本文引用的文献
1
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.《亚太地区慢性乙型肝炎管理共识声明：2012年更新版》
Hepatol Int. 2012 Jun;6(3):531-61. doi: 10.1007/s12072-012-9365-4. Epub 2012 May 17.
2
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?慢性乙型肝炎的最佳治疗方案：我应如何治疗 HBeAg 阳性患者？
Liver Int. 2015 Jan;35 Suppl 1:100-6. doi: 10.1111/liv.12719.
3
Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?对于慢性乙型肝炎患者而言，在考虑核苷（酸）类似物治疗之前先试用干扰素是否更具成本效益？
Clin Gastroenterol Hepatol. 2015 Feb;13(2):386-9. doi: 10.1016/j.cgh.2014.08.024. Epub 2014 Aug 23.
4
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.恩替卡韦治疗不能消除慢性乙型肝炎患者肝细胞癌的风险：风险评分在白种人中作用有限。
Gut. 2015 Aug;64(8):1289-95. doi: 10.1136/gutjnl-2014-307023. Epub 2014 Jul 10.
5
Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B.应答指导下聚乙二醇干扰素治疗慢性乙型肝炎的成本效果分析。
Clin Gastroenterol Hepatol. 2015 Feb;13(2):377-385.e5. doi: 10.1016/j.cgh.2014.06.022. Epub 2014 Jun 30.
6
Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects.替比夫定对肾功能的潜在益处并不超过其高抗病毒耐药率及其他不良反应。
Gastroenterology. 2014 Jan;146(1):15-9. doi: 10.1053/j.gastro.2013.11.028. Epub 2013 Nov 22.
7
Telbivudine improves renal function in patients with chronic hepatitis B.替比夫定可改善慢性乙型肝炎患者的肾功能。
Gastroenterology. 2014 Jan;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031. Epub 2013 Sep 22.
8
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.6 年替诺福韦酯治疗慢性乙型肝炎患者中未检测到耐药性。
Hepatology. 2014 Feb;59(2):434-42. doi: 10.1002/hep.26686.
9
Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.恩替卡韦治疗乙型肝炎 e 抗原阴性慢性乙型肝炎患者停药后应答的持久性。
Hepatology. 2013 Dec;58(6):1888-96. doi: 10.1002/hep.26549. Epub 2013 Oct 17.
10
Management of hepatitis B: our practice and how it relates to the guidelines.乙型肝炎管理：我们的实践及其与指南的关系。
Clin Gastroenterol Hepatol. 2014 Jan;12(1):16-26. doi: 10.1016/j.cgh.2013.04.036. Epub 2013 May 6.
Zotero 插件